| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8213858 | International Journal of Radiation Oncology*Biology*Physics | 2016 | 16 Pages |
Abstract
We found that both ablative and conventionally fractionated RT can be safely administered with ipilimumab without a clinically apparent increase in toxicity. Patients who received ipilimumab before RT had an increased duration of irradiated tumor response.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Rosie BS, Adam MD, Bhavana MD, Samantha MS, Steven MS, Nrupen A. PhD, MPH, Brent A. MD, PhD, Joseph K. MD, April K.S. MD,